Comparative Pharmacology
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus PLUVICTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus PLUVICTO.
MPI INDIUM DTPA IN 111 vs PLUVICTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent that binds to prostate-specific membrane antigen (PSMA), which is overexpressed on prostate cancer cells. After binding, the radioactive isotope lutetium-177 emits beta particles, causing DNA damage and cell death.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) is administered intravenously at a dose of 7.4 GBq (200 mCi) every 6 weeks for up to 6 doses, in combination with a gonadotropin-releasing hormone (GnRH) analog or after prior unilateral orchiectomy.
None Documented
None Documented
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Effective half-life of lutetium-177 is approximately 160 hours (6.67 days), reflecting both physical decay (T1/2 6.647 days) and biological clearance. Clinical context: Due to physical decay, therapeutic radioactivity decreases to <1% after about 45 days.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Primarily renal; approximately 60% of administered radioactivity excreted in urine within 24 hours, with gradual elimination thereafter. Biliary/fecal excretion accounts for <15%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical